Jolanda Howe Sells 1,840 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 1,840 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $105.29, for a total value of $193,733.60. Following the completion of the transaction, the senior vice president directly owned 1,274 shares in the company, valued at approximately $134,139.46. This represents a 59.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $120.00, for a total transaction of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock traded up $1.46 during mid-day trading on Wednesday, hitting $105.79. The company had a trading volume of 818,160 shares, compared to its average volume of 885,530. Mirum Pharmaceuticals, Inc. has a 52-week low of $50.25 and a 52-week high of $130.00. The stock’s 50 day moving average price is $110.29 and its 200-day moving average price is $101.68. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The company has a market capitalization of $6.45 billion, a P/E ratio of -7.77 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%. Equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIRM. Cullen Frost Bankers Inc. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth about $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $32,000. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $33,000. Finally, Comerica Bank raised its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period.

Wall Street Analyst Weigh In

A number of research firms recently commented on MIRM. Citizens Jmp boosted their target price on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a research report on Monday, June 15th. Wall Street Zen cut Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings downgraded Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Morgan Stanley upped their price objective on Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Thursday, June 11th. Finally, Evercore reissued an “outperform” rating and issued a $138.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $143.40.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.